Compounds > maprotiline

maprotiline and selegiline

maprotiline has been researched along with selegiline in 12 studies

Research

Studies (12)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (8.33)	18.2507
2000's	7 (58.33)	29.6817
2010's	4 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Topliss, JG; Yoshida, F	1
Adkison, KK; Humphreys, JE; Mahar Doan, KM; Polli, JW; Serabjit-Singh, CJ; Shampine, LJ; Webster, LO; Wring, SA	1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL	1
Bleich, S; Gulbins, E; Kornhuber, J; Reichel, M; Terfloth, L; Tripal, P; Wiltfang, J	1
Lombardo, F; Obach, RS; Waters, NJ	1
Ahman, M; Holmén, AG; Wan, H	1
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM	1
Gozalbes, R; Pineda-Lucena, A	1
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY	1
Bellman, K; Knegtel, RM; Settimo, L	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Lefebvre, H; Moore, N; Noblet, C; Wolf, LM	1

Reviews

1 review(s) available for maprotiline and selegiline

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Other Studies

11 other study(ies) available for maprotiline and selegiline

Article	Year
QSAR model for drug human oral bioavailability. Journal of medicinal chemistry, 2000, Jun-29, Volume: 43, Issue:13 Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship	2000
Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. The Journal of pharmacology and experimental therapeutics, 2002, Volume: 303, Issue:3 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Cell Line; Cell Membrane Permeability; Central Nervous System Agents; Dogs; Drug Delivery Systems; Permeability; Pharmaceutical Preparations	2002
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Current drug discovery technologies, 2004, Volume: 1, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration	2004
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model. Journal of medicinal chemistry, 2008, Jan-24, Volume: 51, Issue:2 Topics: Algorithms; Animals; Cell Line; Cell Line, Tumor; Chemical Phenomena; Chemistry, Physical; Enzyme Inhibitors; Humans; Hydrogen-Ion Concentration; Molecular Conformation; Quantitative Structure-Activity Relationship; Rats; Sphingomyelin Phosphodiesterase	2008
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7 Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding	2008
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs. Journal of medicinal chemistry, 2009, Mar-26, Volume: 52, Issue:6 Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry	2009
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models. Toxicology mechanisms and methods, 2008, Volume: 18, Issue:2-3 Topics:	2008
QSAR-based solubility model for drug-like compounds. Bioorganic & medicinal chemistry, 2010, Oct-01, Volume: 18, Issue:19 Topics: Databases, Factual; Models, Molecular; Pharmaceutical Preparations; Quantitative Structure-Activity Relationship; Solubility; Water	2010
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. Chemical research in toxicology, 2012, Oct-15, Volume: 25, Issue:10 Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding	2012
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds. Pharmaceutical research, 2014, Volume: 31, Issue:4 Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation	2014
Pseudo-phaeochromocytoma after multiple drug interactions involving the selective monoamine oxidase inhibitor selegiline. Clinical endocrinology, 1995, Volume: 42, Issue:1 Topics: Bronchial Spasm; Bronchitis; Depressive Disorder; Diagnosis, Differential; Drug Interactions; Ephedrine; Epinephrine; Humans; Hypertension; Male; Maprotiline; Middle Aged; Norepinephrine; Parkinson Disease; Pheochromocytoma; Selegiline	1995